Sibutramine offers a new opportunity to provide a comprehensive weight reduction programme for many overweight and obese patients. A methodical and team approach to managing patients on sibutramine plus diet and exercise should hold the key to the best use of this adjunctive therapy in real clinical practice. This paper provides an overview of how to care for patients who are in need of weight management, and shows that simple measures and well organised, good clinical practice are all that is required to achieve clinically important weight reduction and longer term care. International Journal of Obesity (2001) 25, Suppl 4, S34 -S38.
Introduction
The introduction of sibutramine in Europe offers a new opportunity to engage the interest of primary care physicians in managing the health of their obese patients. To make the most of this opportunity, the advice we provide must recognise that management will be in a primary care setting with the inevitable issues of time limitations and the large number of potential patients that require treatment.
Guidance offered should help doctors to identify those most in need of help and those most likely to succeed so that appropriate interventions can be targeted to these patients. Doctors are likely to continue to treat obesity only if they see tangible results from the time spent with their obese patients so a blueprint for best clinical practice obesity management, which may incorporate sibutramine, is needed to help primary care physicians maximise their success.
Seminars were held at 'The Role of Sibutramine in Weight Management' symposium with all the invited delegates being asked to contribute towards a more effective scheme for obesity management. The symposium strategy was to base individual seminars around the particular problems of 10 different clinical cases with a variety of problems in order to highlight issues relating to specific time points in the management process.
Team approach to care
All agreed that managing obesity effectively requires a team approach. Everyone in a healthcare team, including doctors, nurses, receptionists, dietitians, psychologists, physiotherapists, community and commercial groups, has a part to play. In Europe it became clear that there are many different forms of clinical practice at both the primary and referral centre level and often the personnel with the range of skills is lacking. Nevertheless, the expertise and benefits of the specialist knowledge need to be incorporated into a doctor's scheme for patient management. There is now, therefore, often a need to reorganise both the physical conditions and the procedures within a clinic or health centre so that the range of issues and approaches can be taken on board. The time for consultations, particularly at a primary care level, is short, so a systematised approach to care can help to ensure that the doctor's time for patient care is used maximally and the response to patient needs is not just dictated by the availability of physician appointments.
Patient recruitment
If doctors have responsibilities for a community or a defined group of children and adults, rather than simply responding to requests for help, they should recognise that medical care begins with recruitment into treatment and=or prevention. An active approach to identifying individuals in need of help is clearly required to stem the growing tide of obesity ( Figure  1 ). Awareness campaigns promoted by doctors within their own settings and highlighting the risks of obesity are important, but so too is opportunistic recognition of obesity in patients requesting a consultation for completely unrelated conditions. This and an audit of the patients already in our care for other medical problems such as diabetes and cardiovascular diseases including hypertension or arthritis and respiratory disorders are also required and therefore become the responsibility of all medical practitioners.
Public education campaigns, which will help to drive patient recruitment, need to emphasise readily understandable indicators of particular risk so that we can target population groups at greatest risk from obesity and its complications. One important public health message that needs to be promoted more effectively than at present is the importance of a high waist circumference measurement. More effort is needed to reach and motivate men who currently underestimate the dangers of their obesity. Ethnic groups at greater risk for diabetes, such as the large Asian populations in Europe, need special assessment even if they are only modestly overweight; they may require tailored dietary advice to achieve specific weight reduction goals.
Successful local or general health education will encourage patients to self-refer and to recognise their obesity so it will be important for practice teams to develop systems to respond to a growing demand. The role of clinic reception and nursing staff in this task cannot be underestimated. With correct training and support, they can help to prioritise the patient caseload into those with the most urgent need for care and intervention, and can help to direct the many slightly overweight individuals who may become 'the worried well' but still need general preventive advice.
Those overweight and obese patients with medical complications require thorough assessment.
Patient assessment
The sibutramine blueprint begins with a full medical history to include an assessment of diet and exercise, duration of obesity and previous attempts to lose weight. Patients themselves, using standardised protocols and forms in conjunction with para-medical help, can carry out much of this preliminary assessment.
Patients identified as obese need to be thoroughly assessed to gather relevant information on medical history, and to determine their attitude to intervention. Physical examinations will help with the assessment of the differential impact of obesity and other disorders on symptoms such as breathlessness.
Key physical examinations include calculation of body mass index (BMI), measurement of waist circumference and the proper assessment of blood pressure in the seated, rested patient and with the use of a large cuff.
As a rule, the patient should be seated comfortably for at least 5 min with the arm bared, supported and positioned at The role of sibutramine WPT James and N Finer the level of the heart. No caffeine or smoking should be allowed for 30 min prior to the blood pressure measurement. The width of the cuff bladder should be equal to about twothirds of the distance from the axilla to the antecubital space and encircle at least 80% of the arm. False high readings may occur with bladders that are either too narrow or too short. If the bladder does not completely encircle the arm, care must be taken to place the cuff over the brachial artery, whereby the lower edge of the cuff should be about 2.5 cm above the antecubital space. In extremely obese patients, a thigh cuff may be used with the wide bladder folded on itself or the bladder may be placed on the forearm with auscultation over the radial artery. On each occasion at least two readings should be taken: if these vary by more that 5 mmHg, additional readings should be taken until these are close. The arm and cuff size should be noted for each occasion. Other tests can be kept to a few basic ones (Table 1) .
Simple questionnaires can help profile the patient and their lifestyle history; they are easily administered by nursing and administrative staff, and give a good indication of whether the patient wants to lose weight, the expected degree of weight loss and their willingness to enter into an obesity intervention programme.
After close patient assessment, comes the time for decision-making. It is important to prioritise, for each patient, which risk factor should be the initial focus for attention and outcome evaluation. The list may be long but should recognise our capacity now to estimate the probability of cardiovascular events, the commonest cause of death and disability, based on the sex, age, smoking, diabetic status, blood pressure and lipid status of the patient. This quantitative risk evaluation of the probability of a cardiovascular event within 5 or 10 y helps focus both the clinical team and patient on the value of weight reduction to improve blood pressure, lipid or diabetic control and of the importance of stopping smoking which in turn requires concomitant weight management to prevent further weight gain. This means, therefore, that a weight management programme needs to be presented in conjunction with other more traditional management schemes for cessation or reduction of smoking and altering dietary lipids=salt intake as well as psychological support and the specific management of comorbidities.
Initiation of weight management with sibutramine
When instigating a weight management programme, it is important to select a programme that best suits the patient's profile and needs. Key decision drivers are described in Table  2 . Any programme should make close reference to existing local or national guidelines and recommendations and should not only set goals and targets for weight loss, for example, 10% loss of body weight, but also explicitly establish critical monitoring criteria for use in the entire management process. Identifying those patients suitable for a weight reduction programme that includes sibutramine is an important step, as is choosing the best diet and exercise regimen for the individual. At this stage, it is essential to have in place good control of existing comorbidities as well as having carried out 'baseline' checks on vital cardiovascular parameters, such as blood pressure and heart rate, using, in particular, suitable cuff-sizes for blood pressure monitoring and recognising the need for repeated monitoring of blood pressure to overcome the well-known normal variation in normal blood pressure.
Involving patients in their own goal setting is important. The process should be one in which the patient feels comfortable and engaged and thereby agrees to his or her own goals. The goals should be realistic and achievable -care should be taken not to set goals that are too ambitious. It is important that the patient's expectations are carefully managed at this crucial early stage.
Selecting the best team for patient care is also important. A multidisciplinary approach to management will allow the range of necessary expertise to be involved and a sharing of the caseload. Not all the expertise need be either on-site or of a medical nature, so external support and exercise groups may prove to be particularly valuable if properly assessed in terms of their efficacy. Compliance with therapy is no less important than good guidance and support on the best form of exercise and appropriate dietary advice to suit a patient's circumstances. This may require many doctors to learn new techniques once they have recognised the need to know how to evaluate, for example, the energy needs of their patients and then provide specific guidance on the quantities and frequency for eating particular foods and engaging in a structured programme of progressive exercise and new activities. It should be borne in mind that better results are obtained in those patients who do more exercise.
There are many new schemes developed by others and not included in the traditional medical curriculum. For example, one simple scheme involving sibutramine is the so-called 10, 20, 30 regimen which suggests: 10 mg sibutramine; 20% less food, ie not a standardised 1000 kcal diet but one tailored to the individual's current energy needs at their higher body weight; at least 30 min of physical activity every day, even if taken as three separate 10 min walks.
Recent guidelines published by the American Heart Association have suggested that 30 min of exercise per day can reduce the risk of heart disease by up to 40%, although in some patients, eg those with arthritis, even this modest amount will be difficult to achieve.
1 Emerging evidence also suggests the need for more exercise to maintain weight stability unless great care is taken to maintain permanently the lower energy intake from a bulkier, low fat, low sugar diet. In addition, a percentage target for food reduction for obese patients may be more achievable than the prescription of a very low calorie diet, which might be too rigorous at the initiation of such a programme and puts very heavy patients into a severe state of energy imbalance which can trigger metabolic, appetitive and behavioural problems.
A 2-week follow-up visit should be booked at the outset of the programme, providing a vital early milestone along the course of patient management. This is an opportunity to assess treatment safety and tolerability, and to discuss early progress with the patient. An early response to patient problems with the new programme may also help to gain greater commitment, which is particularly important for the overweight patient with diabetes.
One-month visit
As early as 1 month after initiation of a programme with sibutramine, it should be possible, in patients with no major comorbidities, to gauge whether the weight reduction programme could be successful in the longer term. This is the time to identify problems the patient may have with the programme, to reinforce the team approach to management and to bolster the patient's motivation.
By re-emphasising the logic and value of progressive modest weight loss, patients can be helped to understand the principles as well as the medical value of obesity treatment. The dose of sibutramine may be adjusted and the impact of the programme so far on medical risk factors assessed (Figure 2 ), but it must be appreciated that lipid and some other metabolic changes take far longer than a month to adjust and may require later weight stabilisation before becoming fully evident.
For the patient with type 2 diabetes, it is a chance to provide assurance that, although weight loss may be slower than in non-diabetics, it can continue to benefit glycaemic control. Current evidence suggests that benefits in life expectancy as well as in the prevention of cardiovascular events will come to patients with diabetes if great attention is paid to weight loss and if early poor responses are a stimulus to new efforts and not followed by a simple acceptance of the status quo.
Weight plateau phase -3 -6 months
After the first 3 -6 months of a year-long programme, it is important to review achievements and to consider the next stage of the weight management rather than simply weight loss with the patient.
In addition to reviewing the achievements in terms of weight loss and improvements in risk factors and metabolic parameters, now is a good time to discuss with the patient the observed impact of weight reduction on their quality of life, and to have them recognise the remarkable benefits which they may have seen -too often they later forget these benefits and then fail to use them as reinforcement for maintaining good weight stability. At this stage it is important to discuss the future goals of the programme. This visit is also a time to emphasise the chronic nature of obesity to patients and to discuss the longer-term options for weight control.
A plateau in weight loss is almost always found at this time, and it is essential to explain to patients the energetic basis for this plateau and the benefits of maintaining their current lower intake permanently if they are to sustain the achieved weight loss. For those patients where ongoing weight loss is a realistic goal, continued physician, dietary and lifestyle support will be necessary to reduce further the energy intake and=or increase, permanently, the amount of daily exercise. Sibutramine helps substantially to maintain these changes and is not a substitute for the altered lifestyle.
Summary
The scheme or early blueprint arising from this symposium reflects the outcome of evidence-based input from our analyses of over 20 sibutramine trials and the views and experience of European obesity experts. It can provide a starting point from which to develop and standardise the care offered to overweight and obese patients.
It is not intended to be a didactic prescription for patient care. It highlights, instead, the tailored care and management to suit patient needs, while ensuring that vital checks on treatment efficacy, safety and suitability are included within a long-term management programme.
This blueprint recognises the chronic nature of obesity and its many complications. The challenge for obesity experts and primary care physicians is how to adopt and develop this preliminary blueprint in their practice. We need to be bold in willingness to report and audit our successes and shortcomings. It is already clear from the meeting that one of the major challenges is to persuade the general practitioner and not just the specialist to change the physical, organisational and technical arrangements for the care of all the clinical consequences of excess weight gain in everyday clinical practice. By sharing our experiences and feeding knowledge into national programmes, training and communication, we can work together to improve the outlook for the many patients who are overweight and obese.
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Is the current treatment working?
• If nurse monitoring patient progress, establish criteria for medical re-involvement
Review and reset goals
• Specify 3-month goal
• Re-emphasise self-monitoring
• Take particular care with men:
-higher absolute risk -sometimes poorer motivation -many clinical schemes and groups suitable and congenial for women only
Check compliance with diet, activity and sibutramine use Figure 2 One-month visit.
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